Coronavirus Update: Lilly’s Antibody EUA Adds To ‘Turnaround’ Hopes On Pandemic
First Antibody Therapy EUA
Executive Summary
Plus: Humainigen announced data from its still-blinded Phase III trial, while Korea's GeneOne advanced a DNA vaccine candidate.
You may also be interested in...
Roche, Lilly Antibody Cocktails Threatened By Delta Plus Variant But More Evidence Needed
Roche and Eli Lilly’s monoclonal antibody cocktails seem to show reduced efficacy against the Delta Plus variant, first identified in Europe, but more evidence might be needed to support the finding. Meanwhile, GSK’s Indian unit is gearing up to submit an application for accelerated approval of sotrovimab.
Lilly’s Bio-Medicines Portfolio Grows To Offset Pressures In Key Markets
Lilly Bio-Medicines president Ilya Yuffa oversees newer products in competitive therapeutic areas and drug classes, but additional indications and new therapies within the group’s immunology, pain and neuroscience focus areas will capitalize on the group’s existing commercial expertise.
Lilly COVID-19 Neutralizing Antibody Combo’s Reduced Infusion Time Offers Advantages For Providers
US FDA's EUA allows lower doses of the two antibodies than were tested in BLAZE-1, which should extend current supply. With Amgen, Lilly hopes to manufacture 1 million doses by mid-year.